安杰思收盘下跌3.32%，滚动市盈率22.76倍，总市值67.13亿元

Company Overview - Anjias Medical Technology Co., Ltd. specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, particularly in the endoscopy sector [1] - The company's main products include GI series, EMR/ESD series, ERCP diagnostic series, and therapeutic instruments [1] - Anjias has received several government honors, including the "Zhejiang Province Export Brand" title and the "Quality Award" from the Linping District Government [1] Financial Performance - For the first half of 2025, the company reported a revenue of 302 million yuan, representing a year-on-year increase of 14.56% [1] - The net profit for the same period was 126 million yuan, with a year-on-year growth of 1.26% [1] - The sales gross margin stood at 70.21% [1] Market Position - As of the latest data, Anjias's rolling price-to-earnings (PE) ratio is 22.76, while the industry average PE ratio is 59.49 [2] - The company's total market capitalization is 6.713 billion yuan [1] - Anjias ranks 48th in the medical device industry based on PE ratio, with the industry median at 40.19 [1][2] Shareholding Structure - As of the 2025 semi-annual report, a total of 10 institutions hold shares in Anjias, including 5 other entities, 4 funds, and 1 brokerage, with a total holding of 17.6384 million shares valued at 1.143 billion yuan [1]